Equity Profile

ACLX

Arcellx, Inc.

Health CareBiotechnology$6.7B

May7Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.02

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its unique approach to cell therapy.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

In the last quarter, Arcellx reported an EPS of -4.07, significantly missing expectations. The stock reacted slightly positively, gaining 0.11% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Arcellx to report a loss this quarter, with a consensus EPS of -1.02 and revenue of $6 million. The market is watching closely for any signs of improvement in financial performance.

Bull Case

If Arcellx can beat EPS expectations and show stronger-than-expected revenue growth, it could signal a turnaround in its financial trajectory, boosting investor confidence.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its ability to execute on its business strategy, leading to further stock declines.

Key Metrics to Watch

EPS

-1.02

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of -1.02?

A better-than-expected EPS could indicate improved operational efficiency and boost investor sentiment.

What revenue figures will Arcellx report, and how do they compare to the $6 million consensus?

Revenue performance is critical for assessing the company's market traction and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for revenue growth driven by new product developments, which could lead to a surprise in earnings.

Supporting Evidence

Options are pricing a 0.52% move but the stock has averaged 2.34% in past quarters, indicating potential for a larger reaction.

The company's recent product advancements may not be fully reflected in analyst estimates.

Key Risk

If revenue exceeds $10 million, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are crucial for determining whether Arcellx can stabilize its financial performance after recent misses.

Bull Confirmed If

An EPS of -0.95 or better, along with revenue exceeding $10 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than -1.11 and revenue below $4 million would signal ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.34%

Pricing cheap

The options market is pricing in a modest move around earnings, suggesting limited expectations for volatility.

Options are pricing a smaller move than the historical average, indicating a potentially undervalued situation.

Detail

30d HV

1.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests a stock increase of about 2.88%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await further guidance.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of 1.40% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on any new product launches or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies.
4Any changes in guidance for future quarters.
5Responses to analyst questions regarding competitive positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BSMReported

Black Stone Minerals, L.P.

RecapView

May4

FOLDAMC

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.02

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

In the last quarter, Arcellx reported an EPS of -4.07, significantly missing expectations. The stock reacted slightly positively, gaining 0.11% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Arcellx to report a loss this quarter, with a consensus EPS of -1.02 and revenue of $6 million. The market is watching closely for any signs of improvement in financial performance.

Bull Case

If Arcellx can beat EPS expectations and show stronger-than-expected revenue growth, it could signal a turnaround in its financial trajectory, boosting investor confidence.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its ability to execute on its business strategy, leading to further stock declines.

Key Metrics to Watch

EPS

-1.02

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of -1.02?

A better-than-expected EPS could indicate improved operational efficiency and boost investor sentiment.

What revenue figures will Arcellx report, and how do they compare to the $6 million consensus?

Revenue performance is critical for assessing the company's market traction and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for revenue growth driven by new product developments, which could lead to a surprise in earnings.

Supporting Evidence

Options are pricing a 0.52% move but the stock has averaged 2.34% in past quarters, indicating potential for a larger reaction.

The company's recent product advancements may not be fully reflected in analyst estimates.

Key Risk

If revenue exceeds $10 million, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are crucial for determining whether Arcellx can stabilize its financial performance after recent misses.

Bull Confirmed If

An EPS of -0.95 or better, along with revenue exceeding $10 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than -1.11 and revenue below $4 million would signal ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.34%

Pricing cheap

The options market is pricing in a modest move around earnings, suggesting limited expectations for volatility.

Options are pricing a smaller move than the historical average, indicating a potentially undervalued situation.

Detail

30d HV

1.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests a stock increase of about 2.88%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted response as investors await further guidance.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of 1.40% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on any new product launches or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies.
4Any changes in guidance for future quarters.
5Responses to analyst questions regarding competitive positioning.